The clarification of the pathological role of CX3CR1/fractalkine/AIM axis in IgA nephropathy

The clarification of the pathological role of CX3CR1/fractalkine/AIM axis in IgA nephropathy - Clarification of the association between disease activity of IgA nephropathy and CX3CR1/fractalkine/AIM expression, and its pathological role.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000011414

Enrollment

Registered

2013-08-12

Start date

2013-08-12

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

IgA nephropathy

Interventions

Collect 3ml of blood and urine samples additionally at routine examinations.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who have been diagnosed with IgA nephropathy by renal biopsy Patients who have not received the tonsillectomy or steroid therapy. Patients who agree to participate in the study.

Exclusion criteria

Exclusion criteria: Patients who will transfer to another hospital during the treatment. Patients who already had tonsillectomy or steroid therapy. Patients who already have started immunosuppressant therapy. Patients decided by the doctor to be unsuitable to the study other than above.

Design outcomes

Primary

Measure	Time frame
Hematuria, urinary protein, serum creatinine, estimated GFR	—

Countries

Japan

Contacts

Public ContactYusuke Suzuki

Juntendo University Division of Nephrology, Department of Internal Medicine

yusuke@juntendo.ac.jp03-5802-1065

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026